Early phase II trial of human rotavirus vaccine candidate RV3

Vaccine

Volumn 20, Issue 23-24, 2002, Pages 2950-2956

  Barnes, Graeme L ^a,b   Lund, Jennifer S ^a   Mitchell, Susan V ^c   De Bruyn, Leonie ^c   Piggford, Leone ^a   Smith, Arnold L ^a   Furmedge, Janine ^a   Masendycz, Paul J ^a   Bugg, Helen C ^a   Bogdanovic Sakran, Nada ^a   Carlin, John B ^a,b   Bishop, Ruth F ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Zenyth Therapeutics Limited Australia   (Australia)

Author keywords

Human rotavirus vaccines; Neonatal strain rotavirus vaccine; Rotavirus vaccines

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ARTICLE; BRONCHIOLITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; HUMAN ROTAVIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SIDE EFFECT; SMALL INTESTINE; VACCINATION; VIRUS EXCRETION; VIRUS INFECTION; VOMITING; WINTER; BLOOD; DRUG TOLERANCE; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; ROTAVIRUS; SAFETY; VIROLOGY; VIRUS REPLICATION;

ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG TOLERANCE; HUMAN; IMMUNIZATION SCHEDULE; INFANT; INTESTINE, SMALL; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SAFETY; SUPPORT, NON-U.S. GOV'T; VIRUS REPLICATION; HUMANS;

EID: 0037178306     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00235-9     Document Type: Article

References (33)

1. Epidemiology of diarrhoeal disease caused by rotavirus
2. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries
3. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: Report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group
4. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children: US Rotavirus Vaccine Efficacy Group
5. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela
6. Review of rotavirus vaccine trials in Finland
7. Intussusception among infants given an oral rotavirus vaccine
8. Surveillance of rotavirus strains in the US: Identification of unusual strains. The National Rotavirus Strain Surveillance System collaborating laboratories
9. Emergence of serotype G9 human rotaviruses in Australia
10. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children
11. Evaluation of the antigenicity and reactogenicity of varying formulations of the rhesus rotavirus-based quadrivalent and the M37 rotavirus vaccine candidates
12. Evaluation of the M37 human rotavirus vaccine in 2-6-month-old infants
13. Safety and immunogenicity of human rotavirus vaccine strain M37 in adults, children, and infants
14. Efficacy of live, attenuated, human rotavirus vaccine 89.12 in infants: A randomized placebo-controlled trial
15. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89.12
16. Clinical immunity after neonatal rotavirus infection: A prospective longitudinal study in young children
17. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate
18. Derivation of neutralizing monoclonal antibodies to human rotaviruses and evidence that an immunodominant neutralization site is shared between serotypes 1 and 3
19. Simple and specific enzyme immunoassay using monoclonal antibodies for serotyping human rotaviruses
20. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens
21. Identification of group A rotavirus gene four types by polymerase chain reaction
22. Estimation of anti-rotavirus immunoglobulin G in human sera by enzyme-linked immunosorbent assay: Expression of results as units derived from a standard curve
23. Evaluation of end-point titration, single dilution and captive enzyme immunoassay for measurement of anti-rotaviral IgA and IgM in infantile secretions and serum
24. Comparison of rotavirus immunoglobulin coproconversion with other indices of rotavirus infection in a longitudinal study in childhood
25. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants
26. Epidemiology of rotavirus serotypes in Melbourne, Australia from 1973 to 1989
27. Relation of VP7 aminoacid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype
28. G3P2 rotaviruses causing diarrhoeal disease in neonates differ in VP4, VP7 and NSP4 sequences from G3P2 strains causing asymptomatic neonatal infection
29. Clinical trials of rotavirus vaccines
30. The development of multivalent rotavirus (strain WC3) reassortant vaccine for infants
31. Shedding of rotavirus after administration of the tetravalent rhesus rotavirus vaccine